These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20522374)

  • 1. Do rare cancers deserve specific strategies for cancer research?
    Casali PG
    Lancet Oncol; 2010 Jun; 11(6):506-7. PubMed ID: 20522374
    [No Abstract]   [Full Text] [Related]  

  • 2. A framework for applying unfamiliar trial designs in studies of rare diseases.
    Gupta S; Faughnan ME; Tomlinson GA; Bayoumi AM
    J Clin Epidemiol; 2011 Oct; 64(10):1085-94. PubMed ID: 21530171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Purposefulness of using fuzzy logic approaches in the rare disease clinical trials].
    Kiseleva TS; Pagava KI; Korinteli IA; Korinteli MG; Shonvadze DN
    Georgian Med News; 2011 Apr; (193):22-4. PubMed ID: 21617269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research methods to change clinical practice for patients with rare cancers.
    Billingham L; Malottki K; Steven N
    Lancet Oncol; 2016 Feb; 17(2):e70-e80. PubMed ID: 26868356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biostatistics in cancer clinical trials].
    Ohashi Y
    Gan To Kagaku Ryoho; 1998 Jan; 25(2):241-52. PubMed ID: 9480646
    [No Abstract]   [Full Text] [Related]  

  • 7. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a multidisciplinary study: design and protocol.
    Marcus F; Towbin JA; Zareba W; Moss A; Calkins H; Brown M; Gear K;
    Circulation; 2003 Jun; 107(23):2975-8. PubMed ID: 12814984
    [No Abstract]   [Full Text] [Related]  

  • 8. Next generation clinical trials.
    Berry DA
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):601-3. PubMed ID: 22236987
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trial design for rare cancers: why a less conventional route may be required.
    Panageas KS
    Expert Rev Clin Pharmacol; 2015; 8(6):661-3. PubMed ID: 26517109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should clinical trials be approached differently for rare cancers?
    Olver I
    Future Oncol; 2016 May; 12(10):1207-9. PubMed ID: 26939845
    [No Abstract]   [Full Text] [Related]  

  • 11. Need to improve clinical trials in rare neurodegenerative disorders.
    Puopolo M; Pocchiari M
    Ann Ist Super Sanita; 2011; 47(1):55-9. PubMed ID: 21430340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistics and the relationship of clinical research to clinical practice.
    Khuder SA; Kahaleh B
    J Rheumatol; 2009 Feb; 36(2):219-20. PubMed ID: 19208555
    [No Abstract]   [Full Text] [Related]  

  • 13. A consistency approach to evaluation of bridging studies and multi-regional trials.
    Tsou HH; Chien TY; Liu JP; Hsiao CF
    Stat Med; 2011 Jul; 30(17):2171-86. PubMed ID: 21590701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing accrual in cooperative group clinical trials.
    Demmy TL; Yasko JM; Collyar DE; Katz ML; Krasnov CL; Borwhat MJ; Battershell A; George SL
    J Clin Oncol; 2004 Aug; 22(15):2997-3002. PubMed ID: 15284251
    [No Abstract]   [Full Text] [Related]  

  • 15. A predictive Bayesian approach to the design and analysis of bridging studies.
    Gould AL; Jin T; Zhang LX; Wang WW
    J Biopharm Stat; 2012 Sep; 22(5):916-34. PubMed ID: 22946940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCI Cooperative Clinical Trials Groups proceed with reorganization: new system aims to improve efficiency and address changing research needs.
    Printz C
    Cancer; 2013 Oct; 119(19):3423-4. PubMed ID: 24078257
    [No Abstract]   [Full Text] [Related]  

  • 17. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Paradigms and pragmatism].
    Healy MJ
    Rev Epidemiol Sante Publique; 1999 Apr; 47(2):185-9. PubMed ID: 10367305
    [No Abstract]   [Full Text] [Related]  

  • 19. Literature review: January-March 2008.
    Patterson SD; Carroll K
    Pharm Stat; 2008; 7(2):147-9. PubMed ID: 18428118
    [No Abstract]   [Full Text] [Related]  

  • 20. Looking ahead: clinical trial design in adult congenital heart disease.
    Khairy P
    Future Cardiol; 2012 Mar; 8(2):297-304. PubMed ID: 22413987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.